HHS invests in U.S. capacity to make COVID-19 molecular tests for providers

The Department of Health and Human Services will use $650 million from the American Rescue Plan Act to expand U.S. capacity to manufacture rapid molecular tests for COVID-19, which hospitals and other health care providers use to diagnose COVID-19, screen patients before surgery and confirm at-home test results.  

“By strengthening our ability to produce these tests in the United States, we will minimize our reliance on imports from overseas, and sustain robust long-term manufacturing throughout 2022,” HHS said. “The funding will also support purchasing raw materials and finished tests to increase our domestic supply of diagnostic tests.”